Medigene AG
XETRA:MDG1
Medigene AG
XETRA:MDG1
Price:
1.43 EUR
-0.69%
Updated:
May 13, 2024
Section:
Relative Value
The Relative Value of one
MDG1
stock under the Base Case scenario is
4.21
EUR.
Compared to the current market price of 1.43 EUR,
Medigene AG
is
Undervalued by 66%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
MDG1
Relative Value
Base Case
4.21
EUR
Undervaluation 66%
Valuation Multiples
Multiples Across Competitors
MDG1 Competitors Multiples
Medigene AG Competitors
Medigene AG Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| DE |
|
Medigene AG
XETRA:MDG1
|
42.1m EUR | 9.3 | -9.9 | -10.4 | -6.9 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
285.6B USD | 5.3 | 59.3 | 12.9 | 19.6 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
165.8B USD | 5.6 | 44.2 | 18.6 | 30.6 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
110.3B USD | 11.2 | 30.4 | 24.6 | 25.7 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
108B USD | 8.2 | 28 | 22.6 | 25.1 | |
| AU |
|
CSL Ltd
ASX:CSL
|
135.2B AUD | 6.3 | 36.1 | 21.8 | 27.1 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
83.2B USD | 3 | 172.8 | 6.9 | 9.1 | |
| US |
|
Moderna Inc
NASDAQ:MRNA
|
46.9B USD | 9.1 | -7.8 | -8.5 | -7.6 | |
| US |
|
Seagen Inc
NASDAQ:SGEN
|
43.1B USD | 18.8 | -57.5 | -61.9 | -55.8 | |
| US |
|
Biogen Inc
NASDAQ:BIIB
|
32.6B USD | 3.4 | 28 | 14.2 | 17.8 | |
| KR |
|
Celltrion Inc
KRX:068270
|
39.5T KRW | 18.2 | 73.8 | 45.2 | 62.2 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
You don't have any saved screeners yet
